ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2011
Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study.Drug delivery · 2018Trial
- Optimized Chitosan Nanoparticles for Enhanced Ciprofloxacin Delivery and Activity Against Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Chitosan-Gum Arabic Coated Nanostructured Lipid Carriers for Enhanced Gastrointestinal Stability of Curcuminoids.ACS omega · 2026Article
- Formulation, Physicochemical Optimization, and Forensic Evaluation of Zinc Oxide- and Curcumin-Loaded Solid Lipid Nanoparticles for Safe Fingerprint Detection in Forensic Medicine.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Design and preparation of novel domperidone loaded polymeric blend electrospun nanofibers for improved oral pharmacodynamic activity.Drug delivery and translational research · 2026Article
- Integration of Synchronizing In Silico, In Vitro, and In Vivo Strategies for the Development of Antipsoriatic Apremilast-loaded Nanostructured Lipid Carrier Embedded in Hydrogel.AAPS PharmSciTech · 2025Article
- Last Fifteen Years of Nanotechnology Application with Our Contribute.Nanomaterials (Basel, Switzerland) · 2025Review
- Addressing filamentous fungi-related onychomycosis in the era of antifungal resistance: assessment ofCurrent medical mycology · 2025Article
- Formulation Strategy and An Overview of Nano-Structured Lipid Carrier-Based Topical Gel as a Novel Drug Delivery System.Pharmaceutical nanotechnology · 2025Review
- Development and Characterization of Novel Combinations and Compositions of Nanostructured Lipid Carrier Formulations Loaded with Trans-Resveratrol for Pulmonary Drug Delivery.Pharmaceutics · 2024Article
- Phytoconstituents-Based Nanotherapeutic Approach for the Effective Management of Joint Inflammatory Condition: Arthritis.Current drug targets · 2024Review
- A comprehensive review on alpha-lipoic acid delivery by nanoparticles.BioImpacts : BI · 2024Review
- Formulation and Optimization of Solid Lipid Nanoparticle-based Gel for Dermal Delivery of Linezolid using Taguchi Design.Recent advances in anti-infective drug discovery · 2024Article
- Tween 80-Based Self-Assembled Mixed Micelles Boost Valsartan Transdermal Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy.Drug delivery and translational research · 2023Review
- Novel Transethosomal Gel Containing Miconazole Nitrate; Development, Characterization, and Enhanced Antifungal Activity.Pharmaceutics · 2023Article
- Date Palm Extract (Plants (Basel, Switzerland) · 2023Article
- Formulation of lemongrass oil (3 Biotech · 2023Article
- Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.Molecules (Basel, Switzerland) · 2023Article
- Dacarbazine-encapsulated solid lipid nanoparticles for skin cancer: physical characterization, stability,Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and the purpose of the studyDomperidone (DOM) is a dopamine- receptor (D(2)) antagonist, widely used in the treatment of motion-sickness. The pharmacokinetic parameters of DOM make it a suitable candidate for development of Solid Lipid Nanoparticle (SLN) and Nanostructured Lipide Carrier (NLC). The purpose of the present investigation was to prepare and evaluate DOM loaded solid lipid nanoparticles (DOM-SLN) and DOM loaded nanostructured lipid carriers (DOM-NLC).
methodsDOM loaded SLN and NLC were prepared by hot homogenization followed by ultrasonication technique, using trimyristin as solid lipid, cetyl recinoleate as liquid lipid and a mixture of soy phosphatidylcholine (99%) and tween 80 as surfactant. SLN and NLC were characterized for particle size, polydispersity index (PDI), zeta potential and entrapment efficiency. The effects of composition of lipid materials and surfactant mixture on the particle size, PDI, zeta potential, drug entrapment efficiency, and in vitro drug release behavior were investigated. DSC analysis was performed to characterize the state of drug and lipid modification. Shape and surface morphology were determined by transmission electron microscopy (TEM). SLN and NLC formulations were subjected to stability study over a period of 40 days.
resultsThe mean particle size, PDI, zeta potential and entrapment efficiency of optimized SLN (SLN1) and NLC were found to be 30.45 nm, 0.156, 12.40 mV, 87.84% and 32.23 nm, 0.160, 10.47 mV, 90.49% respectively. DSC studies revealed that DOM was in an amorphous state and triglycerides were in the β prime form in SLN and NLC. Shape and surface morphology was determined by TEM revealed fairly spherical shape of nanoparticles. In vitro release studies demonstrated that both the SLN and NLC formulations possessed a controlled release over a period of 24 hrs. SLN and NLC formulations were subjected to stability over a period of 40 days. There was no significant (P<0.05) change in particle size, zeta potential, PDI and entrapment efficiency indicating the developed SLN and NLC were fairly stable.
conclusionFairly spherical shaped, stable and controlled release DOM-SLN and DOM-NLC could be prepared by hot homogenization followed by ultrasonication technique.
Indexed as
Identifiers
22615636PMC3232070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.